FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Trodelvy

Drug and asset intelligence for Trodelvy with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 3
Stage: Phase III

Sponsor company

Gilead →

Mechanism of action

Antibody-Drug Conjugate

Recent signals(2)

RegulatoryJune 27, 2026

FDA Approves Supplemental Application for Trodelvy (Sacituzumab Govitecan-Hziy)

The FDA has approved a supplemental application for Trodelvy, a drug developed by Immunomedics Inc.

ClinicalJune 16, 2026

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC

The Phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy and KEYTRUDA has been discontinued due to lack of statistically significant efficacy.

Upcoming milestones(1)

Topline Data

Gilead Sciences — Trodelvy

TROP2 expansion beyond TNBC is critical for Trodelvy revenue durability.

August 28, 2026 · Phase III

Related catalysts(3)

Topline Data

Gilead Sciences — Trodelvy

TROP2 expansion beyond TNBC is critical for Trodelvy revenue durability.

August 28, 2026 · Phase III

Topline Data

Gilead — Trodelvy

June 27, 2026 · N/A

Topline Data

Merck — Trodelvy

June 16, 2026 · N/A

Indications

HR+/HER2- breast cancer →

NSCLC →

Therapeutic areas

Antibody-Drug Conjugate →

NSCLC →

Oncology →

Oncology · Antibody-Drug Conjugate →

Oncology · NSCLC →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.